Marketwire -- London, UK; Brentwood, TN, US: 3 September 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that on 2 September 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Citigroup on behalf of Standard Life Investments Ltd. Details of the interest notified are as follows:
